Cantor Fitzgerald Starts Celgene (CELG) at Buy; Pipeline is Considerable

Article Stock Quotes (1) Comments (0)

Cantor Fitzgerald initiates coverage on Celgene (NASDAQ: CELG) with a Buy. PT $90.00.

Analyst, Mara Goldstein, said, "Celgene is at a critical juncture, with multiple catalysts in the near term that have the ability to deliver on the company's "transformational milestones" objectives that enhance growth prospects and diversify dependence from Revlimid, the flagship product for multiple myeloma."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $80.29 yesterday, with a 52 week range of $51.70-$80.37.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Celgene (CELG) Granted FDA Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer
• Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
• Roth Capital Resumes Summer Infant (SUMR) at Neutral

Create E-mail Alert Related Categories

New Coverage

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?